Search Results - "Gardizi, M."

Complete metabolic response in a patient with repeatedly relapsed non-small cell lung cancer harboring ROS1 gene rearrangement after treatment with crizotinib by Bos, M, Gardizi, M, Schildhaus, H.U, Heukamp, L.C, Geist, T, Kaminsky, B, Zander, T, Nogova, L, Scheffler, M, Dietlein, M, Kobe, C, Holstein, A, Maintz, D, Büttner, R, Wolf, J

“…Abstract A 55-year-old Caucasian woman with lung adenocarcinoma stage IV presented with repeated relapse after treatment with cytotoxic chemotherapy…”
Get full text

Afatinib in Non‐Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors by Schumann, Christian, Sebastian, Martin, Sadjadian, Parvis, Märten, Angela, Abdollahi, A., Aries, S.P., Arntzen, C., Atmaca, A., Basara, N., Borchard, B., Bos, M., Brugger, W., Budweiser, S., Corduan, K., Cortes‐Incio, D., Dallmeier, B., Denzlinger, C., Dittrich, I., Engel‐Riedel, W., Faehling, M., Fertl, A., Fischer, J.R., Fleckenstein, D., Folprecht, G., Forstbauer, A., France, Y., Frickhofen, N., Gardizi, M., Gauler, T., Gessner, C., Gökkurt, E., Görner, M., Grah, C., Greeve, J., Greiner, J., Grohé, C., Grüning, W., Guggenberger, D., Heinrich, B., Hense, G., Hoiczyk, M., Huber, R.M., Illerhaus, G., Jacobs, G., Jung, P., Kern, J., Kersten, J., Kiehl, M., Kisro, J., Knipp, H., Ko, Y.D., Koch, J.U., Koehne, C.H., Kollmeier, J., Kommer, A., Körber, W., Krause, G., Krügel, R., Leistner, R., Liebers, U., Lommatzsch, M., Maintz, C., Mohr, M., Neumeister, W., Overbeck, T., Panse, J., Pelzer, T., Peters, K., Planker, M., Reissig, A., Ritter, M., Sadjadian, P., Sandritter, B., Schatz, M., Scheffler, M., Schmid‐Bindert, G., Schneider, C.P., Schneider‐Kappus, W., Schreiber, J., Schütte, W., Schütz, S., Sebastian, M., Serke, M., Staiger, H., Stehle, I., Stengele, K., Stöhlmacher‐Williams, J., Strapatsas, T., Sulzbach, B., Tessmer, A., Thomas, M., Ukena, D., Wagner, B., Wagner‐Hug, D., Witt, C., Wohlleber, M., Wolf, J., Wricke, K., Zaba, O., Zander, I.

“…Background. Afatinib, an irreversible ErbB family blocker, is approved for treatment of patients with previously untreated non‐small cell lung cancer (NSCLC)…”
Get full text

Comorbidity and Insurance as Predictors of Disability After Traumatic Brain Injury by Gardizi, Elmar, MA, Hanks, Robin A., PhD, Millis, Scott R., PhD, Figueroa, Maritza J., PhD

“…Abstract Objective To examine the unique contribution of self-reported medical comorbidity and insurance type on disability after traumatic brain injury (TBI)…”
Get full text